RASP (Actavia Life Sciences) Debt-to-Asset : 6.20 (As of Mar. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Actavia Life Sciences Debt-to-Asset?

Actavia Life Sciences RASP -87.50% Debt-to-Asset is 6.20 as of Mar. 2024.

Actavia Life Sciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.30 Mil. Actavia Life Sciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.00 Mil. Actavia Life Sciences's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was $0.05 Mil. Actavia Life Sciences's debt to asset for the quarter that ended in Mar. 2024 was 6.20.

Actavia Life Sciences  (OTCPK:RASP) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Actavia Life Sciences Debt-to-Asset Related Terms

Actavia Life Sciences Debt-to-Asset Historical Data

* Premium members only.

The historical data trend for Actavia Life Sciences's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Actavia Life Sciences Debt-to-Asset Chart

Actavia Life Sciences Annual Data
Trend Jun14 Jun15 Jun16 Mar17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.05 15.82 15.18 2.59 2.20

Actavia Life Sciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.23 5.84 2.20 8.69 6.20

RASP vs BWV, FNCH, CWBR: Debt-to-Asset Comparison

For the Biotechnology subindustry, Actavia Life Sciences's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Actavia Life Sciences Debt-to-Asset vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Actavia Life Sciences's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Actavia Life Sciences's Debt-to-Asset falls into.


Actavia Life Sciences Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Actavia Life Sciences's Debt-to-Asset for the fiscal year that ended in Sep. 2023 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0.211 + 0) / 0.096
=2.20

Actavia Life Sciences's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0.304 + 0) / 0.049
=6.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Asset →
What does a Debt-to-Asset of 6.20 mean?
Actavia Life Sciences (RASP) has a Debt-to-Asset of 6.20 as of Mar. 2024. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Actavia Life Sciences and its competitors.
Is Actavia Life Sciences' Debt-to-Asset too high?
Actavia Life Sciences' current Debt-to-Asset is 6.20.
How does Actavia Life Sciences' Debt-to-Asset compare to BWV and FNCH?
Actavia Life Sciences' Debt-to-Asset of 6.20 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Asset for a Biotechnology company?
A good Debt-to-Asset depends on the Biotechnology industry context. However, Debt-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Asset mean?
A high Debt-to-Asset can signal that a stock is expensive relative to its fundamentals. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Actavia Life Sciences and its competitors. Actavia Life Sciences's current Debt-to-Asset is 6.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Actavia Life Sciences stock overvalued right now?
Actavia Life Sciences (RASP) has a current Debt-to-Asset of 6.20. The current Debt-to-Asset is 6.20. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Asset calculated?
Debt-to-Asset is calculated from a company's financial statements. For Actavia Life Sciences (RASP), the current Debt-to-Asset is 6.20 as of Mar. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Actavia Life Sciences Business Description

Address 5 Penn Plaza, No.1954, 19th Floor, New York, NY, USA, 10001
Actavia Life Sciences Inc is a clinical-stage biotechnology company focused on targeted drugs to treat diseases in oncology and immunology, mainly focusing on the treatment of leukemia. Its primary indication is Acute Myeloid Leukemia (AML), which may be fatal within weeks to months, has about a 5-year survival rate of only about 25% and very poor prospects for the long-term survival of patients.